Personalized Medicine Biomarkers Market Analysis Covering Growth Drivers And Future Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Personalized Medicine Biomarkers Market Progress Between 2026 And 2030?
The personalized medicine biomarkers market has seen rapid expansion in recent years. Its valuation is projected to increase from $26.73 billion in 2025 to $31.34 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The historical growth of this market can be attributed to various factors, including advances in genomic research, a rising incidence of cancer, the expansion of targeted therapies, increased utilization of molecular diagnostics, and regulatory support for precision medicine.
The personalized medicine biomarkers market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $58.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.0%. This anticipated growth during the forecast period is primarily driven by factors such as the proliferation of personalized therapeutics, an increasing need for early detection of diseases, advancements in pharmacogenomics, greater investment in the discovery of biomarkers, and broader application across non-oncology areas. Key trends anticipated during the forecast timeframe encompass the increasing embrace of precision treatment methodologies, a greater utilization of biomarkers in cancer care, the expanding integration of companion diagnostics, the development of predictive and prognostic biomarkers, and an intensified emphasis on monitoring treatment responses.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp
What Significant Factors Are Influencing The Personalized Medicine Biomarkers Market Expansion?
The expanding incidence of chronic diseases is anticipated to fuel the expansion of the personalized medicine biomarkers market in the future. These conditions are long-term health issues that develop gradually and endure for a year or longer, necessitating continuous medical care or restricting daily functioning. The increasing occurrence of chronic diseases stems from detrimental lifestyle habits, inadequate nutrition, insufficient physical movement, and elevated stress levels. Personalized medicine biomarkers play a crucial role in customizing treatments for chronic diseases, achieving this by pinpointing effective remedies, forecasting the disease’s advancement, and reducing negative reactions, all informed by a person’s unique genetic and molecular characteristics. As an illustration, in February 2024, the World Health Organization (WHO), a Switzerland-based health authority, projected that new cancer cases would exceed 35 million by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the rising occurrence of chronic diseases is propelling the growth of the personalized medicine biomarkers market.
Which Segment Categories Are Included In The Personalized Medicine Biomarkers Market Segment Analysis?
The personalized medicine biomarkers market covered in this report is segmented –
1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types
2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications
3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring
4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users
Subsegments:
1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers
2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers
3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers
4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers
Which Trends Are Impacting The Progress Of The Personalized Medicine Biomarkers Market?
Leading companies operating in the personalized medicine biomarkers market are seeking regulatory approvals, such as companion diagnostic approval, to enhance precision oncology by more effectively matching patients to targeted therapies. Companion diagnostic approval refers to the regulatory authorization issued by a health authority (such as the FDA) for a diagnostic test specifically designed to identify patients most likely to benefit from a particular therapeutic product or those at increased risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test utilizes next-generation sequencing (NGS) technology to pinpoint genetic mutations in cancer cells, thereby enabling clinicians to select the most suitable treatments based on individual biomarkers. This approval signifies a substantial advancement in precision oncology, aiming to improve the speed and accuracy of treatment selection for cancer patients, thereby enhancing personalized care.
Who Are The Active Companies Shaping The Personalized Medicine Biomarkers Market?
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
Get The Full Personalized Medicine Biomarkers Market Report:
Which Region Is The Leading Market For The Personalized Medicine Biomarkers Market?
North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Personalized Medicine Biomarkers Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Personalized Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
